Trial Profile
A randomized, double blind, placebo and active controlled, dose escalation study to evaluate the safety, tolerability and potential efficacy of a 12-week treatment with YM543 in subjects with type 2 diabetes mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs YM 543 (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 15 Oct 2008 Status changed from recruiting to completed.
- 15 Oct 2008 Actual patient number (97) added as reported by ClinicalTrials.gov.
- 12 Jun 2007 New trial record.